Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Why Mesoblast shares could rise 40% in a year
Broker Notes
Top brokers name 3 ASX shares to buy today
Share Gainers
Why DroneShield, James Hardie, Lifestyle Communities, and Mesoblast shares are storming higher
Share Market News
5 things to watch on the ASX 200 on Wednesday
Share Market News
Why DroneShield, Greatland Resources, Mesoblast, and Web Travel shares are storming higher today
Healthcare Shares
Why did the Mesoblast share price just rocket 13%?
Share Fallers
Why DigiCo, Emerald Resources, Harvey Norman, and Mesoblast shares are dropping today
Share Gainers
3 ASX 200 stocks rocketing higher this week
Healthcare Shares
This ASX 200 biotech's shares are up more than 10% on good news out of the US
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
CSL shares fall on new Trump tariff hit
Share Gainers
3 ASX 200 stocks racing higher in this week's falling market
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
